Effects of calcium antagonists and agonists on isolated human v. saphena magna used for coronary artery bypass grafting and guinea pig’s papillary muscle

Abstract

Background:

The goal of this study was to investigate the movement of contraction-relaxation effects on isolated human blood vessel samples by the actions of amlodipine (CAS 88150-42-9), cerebrocrast (CAS 118790-71-9), diltiazem (CAS 42399-41-7), and a benzimidazole derivative. Additionally, their effects on isometric contraction force and the duration of the action potential (AP) were measured.

Methods:

The experiments were carried out on isolated human v. saphena magna samples and papillary muscles of adult guinea pigs. Isometric contraction and the AP were recorded using a force transducer and standard microelectrode technique.

Results:

Phenylephrine (10⁻⁴ M) caused contractions of vein rings to 928 ± 76.5 mg. All the tested agents at a concentration of 10⁻⁷–10⁻⁴ M significantly relaxed the smooth muscle in a dose-dependent manner. The weakest response was shown by amlodipine. Pre-treatment with 50 >M of amlodipine, diltiazem and benzimidazole for 30 min significantly increased the magnitude of the contraction induced by phenylephrine in concentration-dependent (10⁻⁶–10⁻⁴) fashion but only in the benzimidazole group versus other tested agents and the control. The benzimidazole derivative caused augmentation of isometric contraction of the papillary muscles and negligible lengthening of AP duration; the other agents tested showed opposite effects.

Conclusion:

These results show that agents possessing positive or negative inotropic action significantly relaxed the isolated vein samples precontracted with phenylephrine. These responses point to a different mechanism of action underlying both calcium antagonist and agonist effects even though their action ultimately resulted in vasodilatation.

Key words

1-Acetyl-5,6-dimethoxy-2-methylthiobenzimidazole - Amlodipine - Cerebrocrast - Diltiazem - Guinea pig papillary muscles - Human v. saphena magna

• References

• 1 Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005; 111: 363-8
• 2 Garaliene V. [The main determinants of endothelial dysfunction]. Mediana (Kaunas) 2006; 42: 362-9 Lithuanian. Abstract in English.
• 3 Feletou M, Vanhoutte PM. Endothelial dysfunction: a mul-tifaceted disorder. Am J Physiol Heart Circ Physiol 2006; 291: H985-1002
• 4 Zhang XP, Hintze TH. cAMP signal transduction induces eNOS activation by promoting PKB phosphorylation. Am J Physiol Heart Circ Physiol 2006; 290: H2376-84
• 5 Matsumoto T, Kobayashi T, Kamata K. Phosphodiesterase in the vascular system. J Smooth Muscle Res 2003; 39 (4) 67-86
• 6 Thompson PE, Manganiello V, Degerman E. Re-discovering PDE3 inhibitors – new opportunities for a long neglected target. Curr Top Med Chem 2007; 7: 421-36
• 7 Kwak YL, Oh YJ, Kim SH, Shin HK, Kim JY, Hong YW. Efficacy of pre-emptive milrinone in off-pump coronary artery bypass surgery: comparison between patients with a low and normal pre-graft cardiac index. Eur J Cardiothorac Surg 2004; 26: 687-93
• 8 Klusa V. Cerebrocrast, neuroprotectant, cognition enhancer. Drugs of the Future 1995; 20: 135-8
• 9 Klusa V. Cerebrocrast, a cognition enhancer and neuroprotectant: focus on mitochondrial functions. Auton Autacoid Pharmacol 2006; 26 (1) 60-2
• 10 Briede J, Stivrina M, Vigante B, Stoldere D, Duburs G. Acute effect of antidiabetic 1,4-dihydropyridine compound cerebrocrast on cardiac function and glucose metabolism in isolated, perfused normal rat heart. Cell Biochem Funct 2008; 26: 238-45
• 11 Vicente JAF, Duburs G, Klusa V, Briede J, Klimaviciusa L, Zharkovsky A et al. Cerebrocrast as a neuroprotective, antidiabetic and mitochondrial bioenergetic effector: a putative mechanism of action. In: Moreno AJM, Oliveira PJ, Palmeira CM. eds. Mitochondrial Pharmacology and Toxicology. Transworld Reseach Network, Kerala 2006: 185-9
• 12 Brukshtus AB, Garalene VN, Sirvidite AP, Daukshas VK. Synthesis and cardiotonic activity of 1-acyl-2-methylthio-5,6-dimethoxybenzimidazole derivatives. Pharm Chem J 1995; 29 (5) 328-9
• 13 Garaliene V, Labanauskas L, Brukštus A, Daukšas V. Synthesis and positive inotropic effects of 1-acyl-5,6-dieth-oxy-2-methylthiobenzimidazoles. Arzneimittelforschung 1998; 48: 1137-42
• 14 Garaliene V, Labanauskas L, Brukštus A. Effect of 1-Acyl-5,6-dialkoxy-2-alkylthiobenzo[d]imidazoles on the action potential duration and isometric contraction in guinea pig atrium activated by carbachol and guinea pig heart papillary muscles. Arzneimittelforschung 2006; 56: 282-7
• 15 Early S. Nelson MT. Central role of Ca2+-dependent regulation of vascular tone in vivo. J Appl Physiol 2006; 101: 10-1
• 16 Raggi P, Shaw AM. Epidemiological guidance with coronary artery calcium scoring. Curr Cardiol Rep 2008; 10: 60-6
• 17 Al-Qaisi M, Kharbanda RK, Mittal TK, Donald AE. Measurement of endothelial function and its clinical utility for cardiovascular risk. Vascular Health Risk Management 2008; 4: 647-52
• 18 Manabe S, Sunamori M. Radial artery graft for coronary artery bypass surgery: biological characteristics and clinical outcome. J Card Surg 2006; 21: 102-14
• 19 He GW, Fan Li, Furnary A, Yang Q. A new antispastic solution for arterial grafting: nicardipine and nitroglycerin cocktail in preparation of internal thoracic and radial arteries for coronary surgery. J Thorac Cardiovasc Surg 2008; 136: 673-80
• 20 Attaran S, John L, El-Gamel A. Clinical and potential use of pharmacological agents to reduce radial artery spasm in coronary artery surgery. Ann Thorac Surg 2008; 85: 1483-9
• 21 Steffen HM. Amlodipine – third generation dihydropyri-dine calcium antagonist. J Clin Basic Cardiol 1999; 2 (1) 45-52
• 22 Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists. Ancillary actions of amlodipine. Arteriscler Thromb Vasc Biol 2003; 23: 2155-63
• 23 Shapira OM, Xu A, Vita JA, Aldea GS, Shah N, Shemin RJ et al. Nitroglycerin is superior to diltiazem as a coronary bypass conduit vasodilator. J Thorac Cardiovasc Surg 1999; 117: 906-11
• 24 Ruschithka FT, Noll G, Lüscher TF. Calcium antagonists and endothelial function. J Clin Basic Cardiol 1999; (2) 175-80
• 25 Duburs G, Vigante B, Plotniece A, Krauze A, Sobolevs A, Briede J et al. Dihydropyridine derivatives as bioprotectors. Chemistry Today 2008; 26 (2) 68-70
• 26 Zhang X, Hintze T. Amlodipine releases nitric oxide from canine coronary microvessels. An unexpected mechanism of action of a calcium channel blocking agent. Circulation 1998; 97: 576-80
• 27 Zhang XP, Loke KE, Mital S, Chahwala S, Hintze TH. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. J Cardiovasc Pharmacol 2002; 39: 208-14
• 28 Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH. K⁺ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998; 396: 269-72
• 29 Stankevicius E, Hughes AD, Simonsen U. K⁺ channels and release of nitric oxide. Fund Clin Pharmacol 2008; 22 (2) 9
• 30 Brekke JF, Jackon WF, Segal SS. Arteriolar smooth muscle Ca²⁺ dynamics during blood flow control in hamster cheek pouch. J Appl Physiol 2006; 101: 307-15
• 31 Kudej RK, Zhang XP, Ghalen B, Huang CH, Jackson JB, Kudej AB et al. Enhanced cAMP-induced nitric oxide-dependent coronary dilation during myocardial stunning in conscious pigs. Am J Physiol Heart Circ Physiol 2000; 279: H2967-74
• 32 Levy JH, Bailey JM, Deeb GM. Intravenous milrinone in cardiac surgery. Ann Thorac Surgery 2002; 73: 325-30
• 33 Feletou M. Calcium-activated potassium channels and endothelial dysfunction: therapeutic options?. Br J Pharmacol 2009; 156: 545-62
• 34 Porter VA, Bonev AD, Knot HJ, Heppner TJ, Stevenson AS, Kleppisch T et al. Frequency modulation of Ca²⁺ sparks is involved in regulation of arterial diameter by cyclic nucleotides. Am J Physiol (Cell Physiol. 43) 1998; 274 (5 Pt 1) C1346-55
• 35 Feng J, Liu Y, Clements RT, Sodha NR, Khabbaz K, Senthilnathan V et al. Calcium-activated potassium channels contribute to human coronary microvascular dysfunction after cardioplegic arrest. Circulation 2008; 118: S46-51
• 36 Zhang XP, Tada H, Wang Z, Hintze TH. cAMP signal transduction, a potential compensatory pathway for coronary endothelial NO production after heart failure. Arterioscler Thromb Vasc Biol 2002; 22: 1273-8
• 37 Bers DM. Calcium and cardiac rhythms. Physiological and pathophysiological. Circ Res 2002; 90: 14-7
• 38 Ademuyiwa AS, Blatter AA, Blatter LA. Modulation of intracellular Ca²⁺ release and capacitative Ca²⁺ entry by CAMKII inhibitors in bovine vascular endothelial cells. Am J Physiol Cell Physiol 2005; 289: C1426-36